INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...

IDEXX Laboratories' oncology panel and share buybacks boost outlook. Read why IDXX stock is upgraded to buy with growth ...

ARC101, a potential best-in-class T-cell engager that targets solid tumors expressing CLDN6, is being assessed in a ...

Pro-immigrant groups warn that the controversy can not, and should not, be just about free speech rights on college campuses.

The prospect of deep Medicaid cuts has become a flashpoint in Congress, with leaders of both parties accusing their counterparts of lying.

In 2025, Cellectis will continue to focus its efforts and expenses on advancing its core clinical trials BALLI-01 and NATHALI ...

Jaguar expects first results in Q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion dis ...

Popular skincare brands are issuing a recall on items sold at retailers including Walgreens and Target over a cancer-linked ...

“The KickStart Grant Awards help de-risk these technologies by establishing a collaboration agreement between the startup ...

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) ("Dogwood" or the "Company"), a development-stage biopharmaceutical company focused on advancing first-in-class, ...

An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the ...

Open label study in forty AML and MDS patientsStudy financed by the US Department of DefenseCantargia (Cantargia AB; Nasdaq Stockholm:CANTA) ...